The drug maker Biogen reported on Wednesday that Aduhelm, its new Alzheimer’s drug, had brought in $300,000 in revenue from July to September, far short of the company’s goals and Wall Street expectations.The sales figures, which Biogen disclosed in its financial report for the third quarter, the drug’s first full period of availability, represented a…
